Patients who undergo total hip or knee replacement surgery may multiply their risk of heart attack 25-fold in the weeks following the procedure, researchers say.
Total knee and hip replacement surgeries may temporarily increase a patient's risk of myocardial infarction during the period immediately after the procedure, researchers said.
The effect was greatest during the 6 weeks following total hip replacement surgery among patients aged 80 and older, who faced a 25.3% increased risk of suffering acute myocardial infarction, according to the study.
The risk was more pronounced in female patients of all ages, for which researchers reported a 21.7% heart attack risk increase compared with 12.8% for male patients.
Histogenics raises $49 million to fund a Phase III trial of its NeoCart regenerative knee cartilage treatment and get CE Mark approval for its VeriCart knee treatment in the European Union.
Histogenics said it raised another $49 million for its regenerative cartilage treatments, as it proceeds with a clinical trial for its NeoCart treatment and pursues CE Mark approval for its VeriCart system.
The round was led by Sofinnova Ventures and including backing from new investors Split Rock Partners, BioMed Ventures and FinTech GIMV Fund. Prior backers ProChon Holdings BV, Altima Partners, Foundation Medical Partners, Inflection Point Capital and Boston Millennia Partners also kicked in.
Group purchasing organization Novation reports on recent trends in orthopedic products, finding upward momentum in spinal devices but slowing growth in U.S. joint markets.
U.S. orthopedics makers faced ups and downs in recent years as the spinal products market continued to expand and growth in hip and knee joint products slowed, according to group purchasing organization Novation.
The total joint market grew by 3.2% between 2009 and 2010, a "sharp decline" from growth of 5.3% the prior year.
Meanwhile, the spinal products market grew by 3.9% between 2010 and 2011 and is expected to grow 2.7% annually to hit $7 billion by 2017, according to the report.
Custom orthopedics implants maker ConforMIS launches a $68 million equity and securities funding round.
Orthopedics devices maker ConforMIS launched a $68 million funding round that will close at the end of this month.
ConforMIS is offering equity, securities and options with no minimum investor, according to regulatory filings.
Rep. Erik Paulsen talks about his device tax repeal playbook, Stryker offers the U.S. Justice Dept. $33 million to settle a knee implants probe and The SEC accuses former Wound Management CEO Scott Haire of running an illegal kickbacks scheme to inflate the company's stock price.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you're still in the know with MassDevice +3.
Orthopedics giant Stryker offers the U.S. Justice Dept. a $33 million settlement to close the books on a probe of its OtisKnee implants.
Michigan-based orthopedics giant Stryker (NYSE:SYK) offered the U.S. Justice Dept. a $33 million settlement to close the books on a federal investigation of its OtisKnee implants.
Rep. Erik Paulsen expects his long-awaited efforts to repeal the medical device tax to reach the House floor this week, he says in the latest episode of his "Correspondence Corner" videos.
MASSDEVICE ON CALL — Rep. Erik Paulsen's long-running effort to repeal the medical device excise tax is nearing a climax in the House, the Congressman said during a recent episode of his regular "Correspondence Corner" videos.
Before answering questions sent by his constituents, Paulsen gave a shout out to Minnesota medical device makers and said he expects his tax repeal bill to get a House vote this week.